Trending
Prev Story
Next Story

Michael Smith

The Australian Financial Review (AFR) •
November 22, 2026 • 06:03:15 AM
2
2 reads 0 reactions

Weight loss means financial gain for pharmacy chains such as Sigma-owned Chemist Warehouse, but direct-to-consumer online platforms may threaten their market share.

Michael Smith

Weight loss means financial gain for pharmacy chains such as Sigma-owned Chemist Warehouse, but direct-to-consumer online platforms may threaten their market share.

The number of Australians taking untested peptide injections to lose weight, build muscle and live longer is soaring, through both legal and illegal channels.

Chief executive Aaron Gray told analysts foreign investment and US competition approvals would not derail the fresh takeover offer.

US pharmaceutical giant Eli Lilly says the medicines regulator has approved its daily tablet known as orforglipron, with stock set to arrive in the coming days.

Aravax says clinical trials show there is hope for a more permanent solution to lethal peanut allergies in children.

The Danish drugmaker has announced the recommended pricing for its Wegovy tablet that is expected to go on sale in Australia by the end of the year.

The launch of the first weight-loss drug pills in Australia is expected to trigger an explosion in the number of people taking the drugs, but at what cost?

He and his brother Jack said in July that they planned to sell up to 20 per cent of their holding in the pharmacy giant.

The government is upgrading offices with alarms, emergency exits and security barriers to protect staff from violent threats.

Shareholders are betting on the sale of Mayne’s US operations once it no longer owns an Australian manufacturing site.

Pricing indications from drugmaker Novo Nordisk suggest its weight loss pill will not be significantly cheaper than the monthly injections.

The Therapeutic Goods Administration has approved Novo Nordisk’s Wegovy pill, a move expected to dramatically increase the number of people taking GLP-1s.

The biotech’s rough 18 months is nothing compared to what happened 20 years ago, with the chairman saying that he’ll finish in March with his head held high.

A new targeted treatment for cancer tumours developed in Melbourne could be worth billions of dollars if human trials are successful.

Big business and providers urge Labor to cut NDIS red tape by 25pc and ditch hourly billing, warning outdated pricing and tech threaten the $50bn scheme’s future.

Company legend Brian McNamee is stepping aside, leaving Gordon Naylor and incoming chief Deborah Waterhouse to drive a turnaround at the blood plasma giant.

Sam Hupert said that hospitals are signing seven-year deals with his software company, defying fears that artificial intelligence will make it obsolete.

Moderna shares tanked after the research data was leaked, but scientist Georgina Long insists it represents a “foundational shift” in melanoma treatment.

Although GLP-1s are a game-changer and growing in demand, Wesfarmers says Australians still have alarming rates of obesity and smoking.

Deborah Waterhouse’s appointment ends months of uncertainty for the blood plasma giant, which fell out of favour with investors after a string of earnings downgrades.

Prev Swipe Story Next

Same Story from Other Publications

Compare how 1 other independent news outlet reported on this story.

1 Publication
RealEstate.com.au News
2d ago
Toorak dominates Melbourne’s most expensive home sales - realestate.com.au

Toorak dominates Melbourne’s most expensive home sales - realestate.com.au

Melbourne’s top sales for the past 12 months have revealed eye-watering purchases, and stamp duty bills. See your area’s biggest price.

#chemist #warehouse
Compare →

Related Stories

Business & Economy
Build #2612